Table 1 Demographic Characteristics of the Patients by Treatment Groups
From: Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
Characteristicsa | All patients (n = 100) | Arbidol group (n = 50) | KALETRA group (n = 50) |
|---|---|---|---|
Age, years (SD)b | 56.4 (16.3) | 56.6 (17.8) | 56.2 (14.8) |
Sex, n (%) | 100 (100) | 50 (100) | 50 (100) |
Male, n (%) | 60 (60) | 33 (66) | 27 (54) |
Female, n (%) | 40 (40) | 17 (34) | 23 (46) |
Marital status, n (%) | 100 (100) | 50 (100) | 50 (100) |
Single, n (%) | 39 (39) | 19 (38) | 20 (40) |
Married, n (%) | 61 (61) | 31 (62) | 30 (60) |
Job, n (%) | 90 (100) | 44 (100) | 46 (100) |
Hospital staff, n (%) | 5 (5.5) | 1 (2.3) | 4 (8.7) |
Self-employment, n (%) | 32 (35.5) | 16 (36.4) | 16 (34.8) |
Housekeeper, n (%) | 35 (38.9) | 15 (34.1) | 20 (43.5) |
Worker, n (%) | 5 (5.6) | 4 (9.1) | 1 (2.2) |
Employee, n (%) | 13 (14.4) | 8 (18.2) | 5 (10.9) |
Smoker, n (%) | 15 (15) | 12 (24) | 3 (6) |
Cigarette per day, n (SD) | 12.2 (11.9) | 13.5 (12.4) | 5 (4.2) |
Smoking duration, years (SD) | 14.6 (8.2) | 14.5 (8.6) | 15 (7) |
Comorbidities, n (%) | 72 (72) | 39 (78) | 33 (66) |
Hypertension, n (%) | 39 (39) | 22 (44) | 17 (34) |
Diabetes, n (%) | 28 (28) | 15 (30) | 13 (26) |
Coronary heart disease, n (%) | 9 (9) | 7 (14) | 2 (4) |
Asthma, n (%) | 2 (2) | 2 (4) | 0 (0) |
Chronic kidney disease, n (%) | 2 (2) | 1 (2) | 1 (2) |
Other diseases, n (%) | 38 (38) | 22 (44) | 16 (32) |